B cells and antibodies in multiple sclerosis pathogenesis and therapy
Authors:
- Tobias DerfussTDTobias Derfuss
- Edgar MeinlEMEdgar Meinl
- 9 October 2012
- journal article
- review article
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 8 (11) , 613-623
Abstract
B cells and antibodies account for the most prominent immunodiagnostic feature in patients with multiple sclerosis (MS), namely oligoclonal bands. Furthermore, evidence is accumulating that B cells and antibodies contribute to MS pathogenesis in at least a subset of patients. The CNS provides a B-cell-fostering environment that includes B-cell trophic factors such as BAFF (B-cell-activating factor of the TNF family), APRIL (a proliferation-inducing ligand), and the plasma-cell survival factor CXCL12. Owing to this environment, the CNS of patients with MS is not only the target of the immunopathological process, but also becomes the site of local antibody production. B cells can increase or dampen CNS inflammation, but their proinflammatory effects seem to be more prominent in most patients, as B-cell depletion is a promising therapeutic strategy. Other therapies not primarily designed to target B cells have numerous effects on the B-cell compartment. This Review summarizes key features of B-cell biology, the role of B cells and antibodies in CNS inflammation, and current attempts to identify the targets of pathogenic antibodies in MS. We also review the effects of approved and investigational interventions-including CD20-depleting antibodies, BAFF/APRIL-depleting agents, alemtuzumab, natalizumab, FTY720, IFN-β, glatiramer acetate, steroids and plasma exchange-on B-cell immunology.Keywords
This publication has 161 references indexed in Scilit:
- A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosisJournal of Neuroimmunology, 2010
- B‐cell activation influences T‐cell polarization and outcome of anti‐CD20 B‐cell depletion in central nervous system autoimmunityAnnals of Neurology, 2010
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- Impact of female cigarette smoking on circulating B cells in vivo: the suppressed ICOSLG, TCF3, and VCAM1 gene functional network may inhibit normal cell functionImmunogenetics, 2010
- Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosisJournal of Neuroimmunology, 2009
- Smoking and Disease Progression in Multiple SclerosisArchives of Neurology, 2009
- Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluidAnnals of Neurology, 2009
- B Lymphocytes Exit Lymph Nodes through Cortical Lymphatic Sinusoids by a Mechanism Independent of Sphingosine-1-Phosphate-Mediated ChemotaxisImmunity, 2009
- Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MSJournal of Neuroimmunology, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006